Welcome to our dedicated page for Creative Med Technology Hldgs news (Ticker: CELZ), a resource for investors and traders seeking the latest updates and insights on Creative Med Technology Hldgs stock.
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) generates frequent news as a clinical-stage biotechnology company advancing regenerative medicine, regenerative immunotherapy, and AI-enabled biodefense programs. News coverage on this page centers on the company’s clinical data, regulatory designations, intellectual property developments, and strategic initiatives built around its AlloStem, ImmCelz, and iPScelz platforms.
Readers can follow detailed updates on CELZ-201 (olastrocel), the company’s lead allogeneic perinatal tissue–derived cell therapy. Recent announcements include interim 180-day results from the FDA-cleared ADAPT trial in chronic lower back pain associated with degenerative disc disease, showing statistically significant and clinically meaningful improvements in functional disability and pain with a favorable safety profile. Additional news highlights FDA Fast Track designation for CELZ-201-DDT and progress in the CREATE-1 trial for new-onset Type 1 diabetes.
CELZ news also covers the company’s BioDefense Inc. subsidiary and its Burn Pit Initiative, which has received regulatory approval to proceed. Articles describe plans to build a large molecular and cellular database for veterans exposed to toxic burn pits, supported by AI-driven molecular modeling and regenerative countermeasure development using the iPScelz platform and collaborations with partners such as Greenstone Biosciences.
Investors can review press releases on patent allowances and issued patents for ImmCelz-based regenerative immunotherapy in Type 1 diabetes and heart failure, as well as corporate communications such as shareholder letters outlining platform strategy, AI integration, and clinical milestones. Capital markets updates, including warrant exercise agreements and related proxy materials, are also reflected in the news flow.
For anyone tracking CELZ, this news feed provides a centralized view of clinical trial milestones, regulatory events, biodefense initiatives, and financing disclosures that shape the company’s development as a clinical-stage biotechnology issuer.
Creative Medical Technology Holdings (CELZ) announced promising proof of concept studies for its ImmCelz® immunotherapy in a collagen-induced rheumatoid arthritis model. The studies highlighted that ImmCelz® effectively suppresses harmful autoimmunity without compromising normal immune functions, potentially reducing treatment-related infection risks. CEO Timothy Warbington noted the potential for rapid clinical application of these findings. ImmCelz® utilizes reprogrammed immune cells derived from adult stem cells, aiming at a significant multi-billion dollar market for autoimmune conditions.
Creative Medical Technology Holdings (OTC-CELZ) has provided an update on its corporate activities, showcasing growth in its stem cell programs. The CaverStem program is expanding, with record kit orders and new practitioners in Houston and Scottsdale. The FemCelz program is gaining traction, and marketing efforts are set to increase. A patent approval for OvaStem highlights progress in treating ovarian failure. The TregSpine and AmnioStem programs are advancing, with an IND application expected in Q4 2020. Despite challenges, the company remains optimistic about its growth.
Creative Medical Technology Holdings announced a Notice of Allowance for its patent on using T regulatory cells to enhance blood circulation for lower back pain treatment. This patent is vital as many patients suffer from poor circulation, contributing to pain. The company also holds a prior patent for stem cell therapy for lower back pain. The CEO highlighted the growing market for such therapies, citing a $1 billion deal in the sector. They are focused on expanding their intellectual property and welcome collaborations within the biotechnology community.
Creative Medical Technology Holdings (CELZ) announced new findings showing that AmnioStem® stem cells can effectively suppress stroke-related pathological molecules. These cells block harmful cytokine production and reprogram macrophages from a damaging to a reparative role, offering a potential advantage over other treatments. The company plans to publish this data and include it in its FDA IND submission. This positions the firm favorably, aiming for FDA clearance and stronger intellectual property protection.